Non‑invasive tests #NITs can be used for early detection and monitoring of #MetALD and alcohol‑related liver disease #ALD. They enable diagnosis before decompensation, improve risk stratification, and reduce biopsy reliance. @AleksanderKrag
https://t.co/8ULyOWWE86
EASL is deeply saddened to share the news of the passing of Professor Michael P. Manns (1951–2025).
A visionary leader in hepatology, Professor Manns shaped the field through his pioneering research in viral hepatitis, autoimmune liver diseases, transplantation and regenerative medicine. He served as Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School for nearly three decades, and held leading roles in Hep-Net, the German Liver Foundation, UEG, and EASL.
His scientific excellence, dedication and mentorship inspired colleagues around the world. Professor Manns received numerous awards, including the EASL Recognition Award (2007) and the UEG Lifetime Achievement Award (2022).
EASL extends heartfelt condolences to his family, friends and colleagues. His legacy will continue to inspire generations of hepatologists.
EASL joins the global hepatology community in mourning the passing of Prof. Jaime Bosch, a visionary clinician-scientist, educator, and leader whose legacy has shaped our field over the past five decades.
From pioneering research in portal hypertension to mentoring generations of hepatologists, Prof. Bosch's contributions have advanced liver care worldwide.
We extend our deepest condolences to his family, friends, and colleagues.
https://t.co/oJWQ6Casgj
@DebbieShawcros1
This week, the General Surgeon in USA warned about ALCOHOL & CANCER.
Why alcohol favors cancer? These are the main 4 reasons:
🔸Its most dangerous metabolite: acetaldehyde.
🔸Oxidative stress.
🔸It increases hormones.
🔸Greater absorption carcinogens.
https://t.co/Y33tnwMZq9
There are novel therapies being tested for hepatitis B to promote functional
cure.
@Mariabutif discusses the promising results from the new drug “bepirovirsen” at the #IMTLD2024
Orgullós de la feina feta! Agrair a tothom que ha fet possible aquesta menció! Principalment en aquelles professionals i amigues que m’han portat pel bon camí amb exigència i rigor, gràcies @Mariabutif@mar_riveiro@vallhebron
We want to identify patients with #cirrhosis early, easily, and while minimizing false alerts
Here’s a group that has done just that:
https://t.co/t1LTJ48USt
Open access #livertwitter in @HepCommJournal
This is the third time that the prestigious Lilly award goes to Hospital valle Hebron: 2022 Josep Tabernero, 2023 Maria Buti, 2024 Xavier Montalban.Congratulations Xavier!!!!